{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:10:26Z","timestamp":1780107026570,"version":"3.54.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M780703"],"award-info":[{"award-number":["2025M780703"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574225"],"award-info":[{"award-number":["82574225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204157"],"award-info":[{"award-number":["82204157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.diabres.2026.113184","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:05:41Z","timestamp":1771891541000},"page":"113184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-9342","authenticated-orcid":false,"given":"Houyu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113184_b0005","unstructured":"World Health Organization. Epilepsy: A public health imperative. 2019. https:\/\/www.who.int\/publications\/i\/item\/epilepsy-a-public-health-imperative. Assessed 09\/12\/2024."},{"key":"10.1016\/j.diabres.2026.113184_b0010","unstructured":"World Health Organization. Epilepsy 2024. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy. Assessed 09\/12\/2024."},{"issue":"4","key":"10.1016\/j.diabres.2026.113184_b0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113184_b0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.diabres.2026.113184_b0025","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1007\/s00210-024-03295-1","article-title":"Exploring the clinical connections between epilepsy and diabetes mellitus: Promising therapeutic strategies utilizing agmatine and metformin","volume":"397","author":"Nangia","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.diabres.2026.113184_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1156952","article-title":"Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor \u03b3 transactivation","volume":"14","author":"Tien","year":"2023","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2026.113184_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2026.113184_b0040","article-title":"Thiazolidinedione an auspicious scaffold as PPAR-\u03b3 agonist: its possible mechanism to Manoeuvre against insulin resistant diabetes mellitus","volume":"11","author":"Basak","year":"2024","journal-title":"Eur J Med Chem Rep"},{"key":"10.1016\/j.diabres.2026.113184_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108316","article-title":"Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives","volume":"241","author":"Senn","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.diabres.2026.113184_b0050","article-title":"Thiazolidinedione use and risk of Parkinson's disease in patients with type 2 diabetes mellitus","volume":"8(1):138","author":"Zhao","year":"2022","journal-title":"npj Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.diabres.2026.113184_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019698","article-title":"Using big data to improve cardiovascular care and outcomes in China: a protocol for the Chinese Electronic health Records Research in Yinzhou (CHERRY) study","volume":"8","author":"Lin","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2026.113184_b0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113184_b0065","doi-asserted-by":"crossref","first-page":"e3036","DOI":"10.1136\/bmjdrc-2022-003036","article-title":"Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus","volume":"10","author":"Newby","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"10.1016\/j.diabres.2026.113184_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144806","article-title":"Rosiglitazone suppresses in vitro seizures in hippocampal slice by inhibiting presynaptic glutamate release in a model of temporal lobe epilepsy","volume":"10","author":"Wong","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.diabres.2026.113184_b0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuint.2013.07.010","article-title":"The PPAR\u03b3 agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF\/TrkB signaling following pilocarpine-induced status epilepticus","volume":"63","author":"Hong","year":"2013","journal-title":"Neurochem Int"},{"issue":"12","key":"10.1016\/j.diabres.2026.113184_b0080","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/cns.13265","article-title":"Rosiglitazone polarizes microglia and protects against pilocarpine-induced status epilepticus","volume":"25","author":"Peng","year":"2019","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.diabres.2026.113184_b0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijdevneu.2008.01.009","article-title":"Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats","volume":"26","author":"Sun","year":"2008","journal-title":"Int J Dev Neurosci"},{"issue":"3","key":"10.1016\/j.diabres.2026.113184_b0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10072-011-0774-2","article-title":"The PPAR\u03b3 agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus","volume":"33","author":"Hong","year":"2012","journal-title":"Neurol Sci"},{"key":"10.1016\/j.diabres.2026.113184_b0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2008.01.047","article-title":"Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus","volume":"1200","author":"Yu","year":"2008","journal-title":"Brain Res"},{"issue":"24","key":"10.1016\/j.diabres.2026.113184_b0100","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113184_b0105","first-page":"267","article-title":"Anticonvulsant and ameliorative effects of pioglitazone on cognitive deficits, inflammation and apoptosis in the hippocampus of rat pups exposed to febrile seizure","volume":"22","author":"Hussein","year":"2019","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"10.1016\/j.diabres.2026.113184_b0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/1753-0407.13352","article-title":"Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: a retrospective cohort study","volume":"15","author":"Zhao","year":"2023","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2026.113184_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.irn.2020.02.010","article-title":"Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones","volume":"155","author":"Cardoso","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.diabres.2026.113184_b0120","unstructured":"National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. NICE Clinical Guidelines 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11822\/."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:46:35Z","timestamp":1780105595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"alternative-id":["S0168822726001038"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113184","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113184"}}